Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges.
GLP-1R-imaging
Minigastrin
Neuroendocrine neoplasms
Somatostatin receptors
Journal
Reviews in endocrine & metabolic disorders
ISSN: 1573-2606
Titre abrégé: Rev Endocr Metab Disord
Pays: Germany
ID NLM: 100940588
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
pubmed:
5
6
2020
medline:
15
12
2021
entrez:
5
6
2020
Statut:
ppublish
Résumé
Neuroendocrine neoplasms (NENs) comprise a heterogeneous group of tumors, mainly localized in the gastrointestinal system. What characterizes NENs is the expression of hormone receptors on the tumor cell surface, making them accessible for diagnostic and therapeutic approaches (theranostics) using radiolabelled peptides. Somatostatin receptors subtype-two (SST2) play an important role in NENs since they are overexpressed and homogeneously distributed at the surface of the majority of NENs. Accordingly, targeting SST2 for diagnostic and therapeutic purposes has been established. Current research aims at upregulating its expression by epigenetic treatment or improving its targeting via use of alternative radioligands. In addition, recent data suggest a future role of SST antagonists as a diagnostic tool and a potential therapeutic option. Another promising target is the glucagon-like peptide-1 (GLP-1) receptor. Targeting GLP-1R using exendin-4 (GLP-1 analogue) has a high sensitivity for the localization of the often SST2-negative sporadic insulinomas and insulinomas in the context of multiple endocrine neoplasia type-1. Further options for patients with insufficient expression of SST2 involve metaiodobenzylguanidine (MIBG) and the molecular target C-X-C motif chemokine receptor-4 (CXCR4), which have been evaluated for potential theranostic approach in symptomatic NENs or dedifferentiated tumors. Recently, new targets such as the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the fibroblast activation protein (FAP) have been identified in NENs. Finally, minigastrin - a ligand targeting the cholecystokinin-2 (CCK2) receptors in medullary thyroid carcinoma and foregut neuroendocrine tumors - may improve future management of these diseases with currently limited therapeutic options. This review summarises the current approaches and future challenges of diagnostic and therapeutic evaluations in neuroendocrine neoplasms.
Identifiants
pubmed: 32495250
doi: 10.1007/s11154-020-09552-x
pii: 10.1007/s11154-020-09552-x
doi:
Substances chimiques
Receptors, Somatostatin
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
581-594Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : P2BSP3_181720
Informations de copyright
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.
Références
Kloppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2011;18(Suppl 1):S1–16.
pubmed: 22005112
doi: 10.1530/ERC-11-0013
Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, et al. Pulmonary neuroendocrine (carcinoid) tumors: European neuroendocrine tumor society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26:1604–20.
pubmed: 25646366
doi: 10.1093/annonc/mdv041
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42.
pubmed: 28448665
pmcid: 5824320
doi: 10.1001/jamaoncol.2017.0589
Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD, Knowledge N. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014;21:R153–63.
pubmed: 24322304
doi: 10.1530/ERC-13-0125
Hofland J, Kaltsas G, de Herder WW. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr Rev. 2019.
Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G, et al. ENETS consensus guidelines for the standards of Care in Neuroendocrine Tumors: pathology: diagnosis and prognostic stratification. Neuroendocrinology. 2017;105:196–200.
pubmed: 28190015
doi: 10.1159/000457956
Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401.
pubmed: 16967267
pmcid: 1888719
doi: 10.1007/s00428-006-0250-1
Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451:757–62.
pubmed: 17674042
doi: 10.1007/s00428-007-0452-1
Inzani F, Petrone G, Rindi G. The New World health organization classification for pancreatic neuroendocrine Neoplasia. Endocrinol Metab Clin N Am. 2018;47:463–70.
doi: 10.1016/j.ecl.2018.04.008
Zandee WT, Kamp K, van Adrichem RC, Feelders RA, de Herder WW. Effect of hormone secretory syndromes on neuroendocrine tumor prognosis. Endocr Relat Cancer. 2017;24:R261–R74.
pubmed: 28483790
doi: 10.1530/ERC-16-0538
Reubi JC, Waser B, Cescato R, Gloor B, Stettler C, Christ E. Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients. J Clin Endocrinol Metab. 2010;95:2343–50.
pubmed: 20228164
pmcid: 2869539
doi: 10.1210/jc.2009-2487
Gatto F, Hofland LJ. The role of somatostatin and dopamine D2 receptors in endocrine tumors. Endocr Relat Cancer. 2011;18:R233–51.
pubmed: 22135243
doi: 10.1530/ERC-10-0334
Wild D, Behe M, Wicki A, et al. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med. 2006;47:2025–33.
pubmed: 17138746
Wild D, Macke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med. 2008;359:766–8.
pubmed: 18703486
doi: 10.1056/NEJMc0802045
Kayano D, Kinuya S. Current consensus on I-131 MIBG therapy. Nucl Med Mol Imaging. 2018;52:254–65.
pubmed: 30100938
pmcid: 6066492
doi: 10.1007/s13139-018-0523-z
Pasieka JL, McEwan AJ, Rorstad O. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery. 2004;136:1218–26.
pubmed: 15657579
doi: 10.1016/j.surg.2004.06.050
Kaemmerer D, Reimann C, Specht E, Wirtz RM, Sayeg M, Baum RP, et al. Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms. Oncotarget. 2015;6:3346–58.
pubmed: 25671300
doi: 10.18632/oncotarget.3242
Kaemmerer D, Trager T, Hoffmeister M, et al. Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy. Oncotarget. 2015;6:27566–79.
pubmed: 26259237
pmcid: 4695009
doi: 10.18632/oncotarget.4491
Gourni E, Waser B, Clerc P, Fourmy D, Reubi JC, Maecke HR. The glucose-dependent insulinotropic polypeptide receptor: a novel target for neuroendocrine tumor imaging-first preclinical studies. J Nucl Med. 2014;55:976–82.
pubmed: 24744444
doi: 10.2967/jnumed.113.133744
Reubi JC, Waser B. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer. 1996;67:644–7.
pubmed: 8782652
doi: 10.1002/(SICI)1097-0215(19960904)67:5<644::AID-IJC9>3.0.CO;2-U
Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-a and CCK-B/gastrin receptors in human tumors. Cancer Res. 1997;57:1377–86.
pubmed: 9102227
Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. (68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of Cancer. J Nucl Med. 2019;60:801–5.
pubmed: 30954939
pmcid: 6581228
doi: 10.2967/jnumed.119.227967
Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, du L, et al. The impact of Somatostatin receptor-directed PET/CT on the Management of Patients with neuroendocrine tumor: a systematic review and meta-analysis. J Nucl Med. 2017;58:756–61.
pubmed: 28082438
doi: 10.2967/jnumed.116.185587
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of (177)Lu-Dotatate for Midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.
pubmed: 28076709
pmcid: 5895095
doi: 10.1056/NEJMoa1607427
Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836–46.
pubmed: 11504080
doi: 10.1007/s002590100541
Reubi JC, Waser B, Liu Q, Laissue JA, Schonbrunn A. Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. J Clin Endocrinol Metab. 2000;85:3882–91.
pubmed: 11061553
Reubi JC. Peptide receptor expression in GEP-NET. Virchows Arch. 2007;451(Suppl 1):S47–50.
pubmed: 17684767
doi: 10.1007/s00428-007-0443-2
Hofland LJ, Liu Q, Van Koetsveld PM, et al. Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. J Clin Endocrinol Metab. 1999;84:775–80.
pubmed: 10022452
doi: 10.1210/jcem.84.2.5497
Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, et al. ENETS consensus guidelines for the standards of Care in Neuroendocrine Tumors: radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology. 2017;105:212–44.
pubmed: 28355596
doi: 10.1159/000471879
Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010;252:850–6.
pubmed: 21037441
doi: 10.1097/SLA.0b013e3181fd37e8
Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. ENETS consensus guidelines for the standards of Care in Neuroendocrine Neoplasia: peptide receptor radionuclide therapy with radiolabeled Somatostatin analogues. Neuroendocrinology. 2017;105:295–309.
pubmed: 28402980
doi: 10.1159/000475526
Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, et al. ENETS consensus guidelines for standard of Care in Neuroendocrine Tumours: surgery for small intestinal and pancreatic neuroendocrine Tumours. Neuroendocrinology. 2017;105:255–65.
pubmed: 28237989
doi: 10.1159/000464292
Veenstra MJ, de Herder WW, Feelders RA, Hofland LJ. Targeting the somatostatin receptor in pituitary and neuroendocrine tumors. Expert Opin Ther Targets. 2013;17:1329–43.
pubmed: 23991721
doi: 10.1517/14728222.2013.830711
Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27:4656–63.
pubmed: 19704057
doi: 10.1200/JCO.2009.22.8510
Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–33.
pubmed: 25014687
doi: 10.1056/NEJMoa1316158
Krenning EP, Kooij PP, Bakker WH, Breeman WA, Postema PT, Kwekkeboom DJ, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci. 1994;733:496–506.
pubmed: 7978900
doi: 10.1111/j.1749-6632.1994.tb17300.x
Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29:2416–23.
pubmed: 21555692
doi: 10.1200/JCO.2010.33.7873
Bergsma H, van Vliet EI, Teunissen JJ, Kam BL, de Herder WW, Peeters RP, et al. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Best Pract Res Clin Gastroenterol. 2012;26:867–81.
pubmed: 23582925
doi: 10.1016/j.bpg.2013.01.004
Bodei L, Kidd M, Modlin IM, Severi S, Drozdov I, Nicolini S, et al. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2016;43:839–51.
pubmed: 26596723
doi: 10.1007/s00259-015-3250-z
Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-Term Efficacy, Survival, and Safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin Cancer Res. 2017;23:4617–24.
pubmed: 28428192
doi: 10.1158/1078-0432.CCR-16-2743
Kashyap R, Hofman MS, Michael M, Kong G, Akhurst T, Eu P, et al. Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2015;42:176–85.
pubmed: 25209134
doi: 10.1007/s00259-014-2906-4
Kong G, Callahan J, Hofman MS, Pattison DA, Akhurst T, Michael M, et al. High clinical and morphologic response using (90)Y-DOTA-octreotate sequenced with (177)Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2017;44:476–89.
pubmed: 27678267
doi: 10.1007/s00259-016-3527-x
Raj N, Reidy-Lagunes D. Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors. Pancreas. 2014;43:1185–9.
pubmed: 25333401
doi: 10.1097/MPA.0000000000000232
Qian ZR, Li T, Ter-Minassian M, et al. Association between Somatostatin receptor expression and clinical outcomes in neuroendocrine tumors. Pancreas. 2016;45:1386–93.
pubmed: 27622342
pmcid: 5067972
doi: 10.1097/MPA.0000000000000700
Okuwaki K, Kida M, Mikami T, Yamauchi H, Imaizumi H, Miyazawa S, et al. Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes. Cancer. 2013;119:4094–102.
pubmed: 24022344
doi: 10.1002/cncr.28341
Duenas-Gonzalez A, Coronel J, Cetina L, Gonzalez-Fierro A, Chavez-Blanco A, Taja-Chayeb L. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer. Expert Opin Drug Metab Toxicol. 2014;10:1433–44.
pubmed: 25154405
doi: 10.1517/17425255.2014.947263
Candelaria M, Burgos S, Ponce M, Espinoza R, Duenas-Gonzalez A. Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP) as epigenetic treatment for myelodysplastic syndrome (MDS). Ann Hematol. 2017;96:1825–32.
pubmed: 28831600
doi: 10.1007/s00277-017-3103-x
Coronel J, Cetina L, Pacheco I, et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol. 2011;28(Suppl 1):S540–6.
pubmed: 20931299
doi: 10.1007/s12032-010-9700-3
Mafficini A, Scarpa A. Genetics and epigenetics of Gastroenteropancreatic neuroendocrine neoplasms. Endocr Rev. 2019;40:506–36.
pubmed: 30657883
pmcid: 6534496
doi: 10.1210/er.2018-00160
Veenstra M, van Koetsveld P, Dogan F, et al. Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells. 2016.
Taelman VF, Radojewski P, Marincek N, et al. Upregulation of key molecules for targeted imaging and therapy. J Nucl Med. 2016;57:1805–10.
pubmed: 27363833
doi: 10.2967/jnumed.115.165092
Wanek J, Gaisberger M, Beyreis M, et al. Pharmacological inhibition of class IIA HDACs by LMK-235 in pancreatic neuroendocrine tumor cells. Int J Mol Sci. 2018;19.
Jin XF, Auernhammer CJ, Ilhan H, Lindner S, Nölting S, Maurer J, et al. Combination of 5-fluorouracil with epigenetic modifiers induces Radiosensitization, Somatostatin receptor 2 expression, and Radioligand binding in neuroendocrine tumor cells in vitro. J Nucl Med. 2019;60:1240–6.
pubmed: 30796167
doi: 10.2967/jnumed.118.224048
Guenter R, Aweda T, Carmona Matos DM, et al. Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment. Surgery. 2019.
Guenter RE, Aweda T, Carmona Matos DM, et al. Pulmonary carcinoid surface receptor modulation using histone Deacetylase inhibitors. Cancers (Basel). 2019;11.
Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, et al. 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J Nucl Med. 2017;58:81–4.
pubmed: 27660139
pmcid: 5209643
doi: 10.2967/jnumed.116.181800
Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A. 2006;103:16436–41.
pubmed: 17056720
pmcid: 1618814
doi: 10.1073/pnas.0607761103
Cescato R, Waser B, Fani M, Reubi JC. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J Nucl Med. 2011;52:1886–90.
pubmed: 22068898
doi: 10.2967/jnumed.111.095778
Fani M, Braun F, Waser B, Beetschen K, Cescato R, Erchegyi J, et al. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. J Nucl Med. 2012;53:1481–9.
pubmed: 22851637
doi: 10.2967/jnumed.112.102764
Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, et al. Sensitivity comparison of (68)Ga-OPS202 and (68)Ga-DOTATOC PET/CT in patients with Gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study. J Nucl Med. 2018;59:915–21.
pubmed: 29191855
doi: 10.2967/jnumed.117.199760
Wild D, Fani M, Fischer R, del Pozzo L, Kaul F, Krebs S, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55:1248–52.
pubmed: 24963127
doi: 10.2967/jnumed.114.138834
Nicolas GP, Mansi R, McDougall L, Kaufmann J, Bouterfa H, Wild D, et al. Biodistribution, pharmacokinetics, and Dosimetry of (177)Lu-, (90)Y-, and (111)in-labeled Somatostatin receptor antagonist OPS201 in comparison to the agonist (177)Lu-DOTATATE: the mass effect. J Nucl Med. 2017;58:1435–41.
pubmed: 28450554
doi: 10.2967/jnumed.117.191684
Reidy-Lagunes D, Pandit-Taskar N, O'Donoghue JA, et al.. Phase I trial of well-differentiated neuroendocrine tumors (NETs) with radiolabeled Somatostatin antagonist 177 Lu-Satoreotide Tetraxetan. Clin Cancer Res 2019.
Nicolas GP, Morgenstern A, Schottelius M, Fani M. New developments in peptide receptor radionuclide therapy. J Nucl Med. 2018.
Marciniak A, Brasun J. Somatostatin analogues labeled with copper radioisotopes: current status. J Radioanal Nucl Chem. 2017;313:279–89.
pubmed: 28804185
pmcid: 5533839
doi: 10.1007/s10967-017-5323-x
Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, et al. Head-to-head comparison of (64)cu-DOTATATE and (68)Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors. J Nucl Med. 2017;58:451–7.
pubmed: 27660147
doi: 10.2967/jnumed.116.180430
Pauwels E, Cleeren F, Bormans G, Deroose CM. Somatostatin receptor PET ligands - the next generation for clinical practice. Am J Nucl Med Mol Imaging. 2018;8:311–31.
pubmed: 30510849
pmcid: 6261874
Price EW, Orvig C. Matching chelators to radiometals for radiopharmaceuticals. Chem Soc Rev. 2014;43:260–90.
pubmed: 24173525
doi: 10.1039/C3CS60304K
Hicks RJ, Jackson P, Kong G, Ware RE, Hofman MS, Pattison DA, et al. (64)cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective Dosimetry for peptide receptor radionuclide therapy. J Nucl Med. 2019;60:777–85.
pubmed: 30442752
pmcid: 6581229
doi: 10.2967/jnumed.118.217745
Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol. 1996;23:957–80.
pubmed: 9004284
doi: 10.1016/S0969-8051(96)00130-8
Ahmedova A, Todorov B, Burdzhiev N, Goze C. Copper radiopharmaceuticals for theranostic applications. Eur J Med Chem. 2018;157:1406–25.
pubmed: 30282317
doi: 10.1016/j.ejmech.2018.08.051
Schottelius M, Wurzer A, Wissmiller K, Beck R, Koch M, Gorpas D, et al. Synthesis and preclinical characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for nuclear and fluorescence imaging of prostate Cancer. J Nucl Med. 2019;60:71–8.
pubmed: 30237214
pmcid: 6354225
doi: 10.2967/jnumed.118.212720
Muller C, Domnanich KA, Umbricht CA, van der Meulen NP. Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application. Br J Radiol. 2018;91:20180074.
pubmed: 29658792
pmcid: 6475947
doi: 10.1259/bjr.20180074
Navalkissoor S, Grossman A. Targeted alpha particle therapy for neuroendocrine Tumours: the next generation of peptide receptor radionuclide therapy. Neuroendocrinology. 2019;108:256–64.
pubmed: 30352433
doi: 10.1159/000494760
Kratochwil C, Giesel FL, Bruchertseifer F, et al. (2)(1)(3)bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41:2106–19.
pubmed: 25070685
pmcid: 4525192
doi: 10.1007/s00259-014-2857-9
Kratochwil C, Bruchertseifer F, Giesel F, et al. Ac-225-DOTATOC - an empiric dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors. J Nucl Med. 2015;56.
Garin E, Le Jeune F, Devillers A, et al. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med. 2009;50:858–64.
pubmed: 19443590
doi: 10.2967/jnumed.108.057505
Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, et al. Dual Somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine Tumours: proposal for a novel grading scheme with prognostic significance. Theranostics. 2017;7:1149–58.
pubmed: 28435454
pmcid: 5399582
doi: 10.7150/thno.18068
Rasul S, Hartenbach S, Rebhan K, Göllner A, Karanikas G, Mayerhoefer M, et al. [(18)F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery. Eur J Nucl Med Mol Imaging. 2018;45:2159–69.
pubmed: 29766245
pmcid: 6182401
doi: 10.1007/s00259-018-4045-9
Houseni M, Chamroonrat W, Zhuang H, Hernandez-Pampolini M, Alavi A. Fluorine-18 DOPA-PET and PET/CT imaging in congenital Hyperinsulinism. PET Clin. 2008;3:577–85.
pubmed: 27156821
doi: 10.1016/j.cpet.2009.04.002
Kroiss AS, Uprimny C, Shulkin BL, Frech A, Tilg H, Gasser RW, et al. Compared to (123)I-MIBG SPECT/CT, (18)F-DOPA PET/CT provides accurate tumor extent in patients with extra-adrenal paraganglioma. Ann Nucl Med. 2017;31:357–65.
pubmed: 28349331
doi: 10.1007/s12149-017-1162-7
Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:1431–8.
pubmed: 18418596
doi: 10.1007/s00259-008-0769-2
Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30:781–93.
pubmed: 12707737
doi: 10.1007/s00259-003-1184-3
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–57.
pubmed: 17498508
doi: 10.1053/j.gastro.2007.03.054
Christ E, Wild D, Forrer F, Brändle M, Sahli R, Clerici T, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab. 2009;94:4398–405.
pubmed: 19820010
doi: 10.1210/jc.2009-1082
Christ E, Wild D, Ederer S, Béhé M, Nicolas G, Caplin ME, et al. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. Lancet Diabetes Endocrinol. 2013;1:115–22.
pubmed: 24622317
doi: 10.1016/S2213-8587(13)70049-4
Antwi K, Fani M, Nicolas G, Rottenburger C, Heye T, Reubi JC, et al. Localization of hidden Insulinomas with (6)(8)Ga-DOTA-Exendin-4 PET/CT: a pilot study. J Nucl Med. 2015;56:1075–8.
pubmed: 25999434
doi: 10.2967/jnumed.115.157768
Antwi K, Fani M, Heye T, Nicolas G, Rottenburger C, Kaul F, et al. Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study. Eur J Nucl Med Mol Imaging. 2018;45:2318–27.
pubmed: 30054698
doi: 10.1007/s00259-018-4101-5
Antwi K, Nicolas G, Fani M, et al. 68Ga-exendin-4 PET/CT detects insulinomas in patients with endogenous hyperinsulinemic hypoglycemia in MEN-1. J Clin Endocrinol Metab. 2019.
van Leeuwaarde RS, van Nesselrooij BP, Hermus AR, Dekkers OM, de Herder WW, van der Horst-Schrivers A, et al. Impact of delay in diagnosis in outcomes in MEN1: results from the Dutch MEN1 study group. J Clin Endocrinol Metab. 2016;101:1159–65.
pubmed: 26751192
doi: 10.1210/jc.2015-3766
Wild D, Christ E, Caplin ME, Kurzawinski TR, Forrer F, Brändle M, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med. 2011;52:1073–8.
pubmed: 21680696
doi: 10.2967/jnumed.110.085142
Jansen TJP, van Lith SAM, Boss M, et al. Exendin-4 analogs in insulinoma theranostics. J Labelled Comp Radiopharm. 2019.
Ezziddin S, Sabet A, Logvinski T, Alkawaldeh K, Yong-Hing CJ, Ahmadzadehfar H, et al. Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors. J Nucl Med. 2013;54:2032–8.
pubmed: 24101685
doi: 10.2967/jnumed.112.119313
Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, et al. Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced Pheochromocytoma or Paraganglioma. J Nucl Med. 2019;60:623–30.
pubmed: 30291194
pmcid: 6495236
doi: 10.2967/jnumed.118.217463
Nastos K, Cheung VTF, Toumpanakis C, Navalkissoor S, Quigley AM, Caplin M, et al. Peptide receptor radionuclide treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas. J Surg Oncol. 2017;115:425–34.
pubmed: 28166370
doi: 10.1002/jso.24553
Mak IYF, Hayes AR, Khoo B, Grossman A. Peptide receptor radionuclide therapy as a novel treatment for metastatic and invasive Phaeochromocytoma and Paraganglioma. Neuroendocrinology. 2019;109:287–98.
pubmed: 30856620
doi: 10.1159/000499497
Werner RA, Weich A, Higuchi T, Schmid JS, Schirbel A, Lassmann M, et al. Imaging of chemokine receptor 4 expression in neuroendocrine tumors - a triple tracer comparative approach. Theranostics. 2017;7:1489–98.
pubmed: 28529632
pmcid: 5436508
doi: 10.7150/thno.18754
Lapa C, Luckerath K, Rudelius M, et al. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience. Oncotarget. 2016;7:9288–95.
pubmed: 26843617
pmcid: 4891040
doi: 10.18632/oncotarget.7063
Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A, Hänscheid H, et al. First-in-human experience of CXCR4-directed Endoradiotherapy with 177Lu- and 90Y-labeled Pentixather in advanced-stage multiple myeloma with extensive intra- and Extramedullary disease. J Nucl Med. 2016;57:248–51.
pubmed: 26564323
doi: 10.2967/jnumed.115.167361
Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567–610.
pubmed: 25810047
pmcid: 4490627
doi: 10.1089/thy.2014.0335
Beukhof CM, Brabander T, van Nederveen FH, et al. Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls. BMC Cancer. 2019;19:325.
pubmed: 30953466
pmcid: 6451300
doi: 10.1186/s12885-019-5540-5
Iten F, Muller B, Schindler C, et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res. 2007;13:6696–702.
pubmed: 18006770
doi: 10.1158/1078-0432.CCR-07-0935
Rottenburger C, Nicolas GP, McDougall L, et al. Cholecystokinin-2 receptor agonist (177)Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma - results of the Lumed phase 0a study. J Nucl Med. 2019.
Kunikowska J, Ziemnicka K, Pawlak D, Ruchała M, Kolasa A, Janicka-Jedyńska M, et al. Medullary thyroid carcinoma - PET/CT imaging with 68Ga-labelled gastrin and somatostatin analogues. Endokrynol Pol. 2016;67:68–71.
pubmed: 26884118
doi: 10.5603/EP.2016.0010
Blazevic A, Hofland J, Hofland LJ, Feelders RA, de Herder WW. Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum. Endocr Relat Cancer. 2018;25:R115–R30.
pubmed: 29233841
doi: 10.1530/ERC-17-0380
Reubi JC, Waser B. Triple-peptide receptor targeting in vitro allows detection of all tested gut and bronchial NETs. J Nucl Med. 2015;56:613–5.
pubmed: 25698785
doi: 10.2967/jnumed.114.153189